"Continued Shortage of Eli Lilly's Zepbound Weight Loss Drug Expected"
Injectable weight loss drugs like Zepbound, Mounjaro, Wegovy, and Ozempic are facing limited availability due to high demand, with most varieties listed as in short supply by the FDA. Eli Lilly, the company behind Zepbound and Mounjaro, expects supply issues to last into 2025 and is working to increase capacity. Similarly, Novo Nordisk is also working to ramp up the supply of its weight loss drug, Wegovy. Patients are advised to check with local pharmacies frequently and plan refills ahead of time, as shortages are expected to continue.